Your email has been successfully added to our mailing list.

×
0 0 -0.00970873786407768 0 0 0.0194174757281554 0.0145631067961166 0.0388349514563107
Stock impact report

Lucid Diagnostics reports Q3 results [Seeking Alpha]

Lucid Diagnostics Inc. (LUCD) 
Company Research Source: Seeking Alpha
Lucid had cash and cash equivalents of $14.5M as of Sept. 30, 2024, compared to $18.9M as of Dec. 31, 2023. More on Lucid Diagnostics Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test Lucid Diagnostics to be deconsolidated from PAVmed's financial statements Seeking Alpha's Quant Rating on Lucid Diagnostics Historical earnings data for Lucid Diagnostics Financial information for Lucid Diagnostics Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for LUCD alerts
Opt-in for
LUCD alerts

from News Quantified
Opt-in for
LUCD alerts

from News Quantified